Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

AngelosProject Apr. 20 at 11:51 PM

$VITL $MRAM $CROX $ABCL lbcd

0 · Reply

SpaceRunners Apr. 20 at 10:49 PM

$CLOV $RVSN $PFE $ABCL XO

1 · Reply

AngelosProject Apr. 20 at 10:21 PM

$ABCL $GNS $GEVO $MRAM canc

0 · Reply

8008track Apr. 20 at 9:30 PM

$ABCL AbCellerites growing https://x.com/tyler_bosserman/status/2046306534477500711?s=46&t=19IS2lnKv9JueG0DGj5x7Q

0 · Reply

tradersunion353 Apr. 20 at 8:42 PM

$ABCL POS performance as usual. Lets see with that data on earnings day. Too much overhyped and very disaapointing performance stock,.

0 · Reply

AngelosProject Apr. 20 at 8:28 PM

$ABCL $ROG $MDCX $CUE ank

1 · Reply

AcceleratorModel Apr. 20 at 8:00 PM

$ABCL got sum at the bell , 3.91

0 · Reply

UncleTomFlorida Apr. 20 at 7:48 PM

$ABCL https://x.com/JackPrescottX/status/2046310840140534077?s=20

0 · Reply

DragonAlgo Apr. 20 at 7:15 PM

🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2027-01-15 | Strike: $4.00 | Type: CALL Option Plan (premium): Entry: $1.40 Stop: $1.01 TP1: $1.82 TP2: $2.38 TP3: $3.36 Momentum tape remains active. 🔗 https://dragonalgo.com

0 · Reply

Rastafari Apr. 20 at 7:12 PM

$ABCL quick poll: do we close up, down or even today. It seems the big boys are trying to keep it down. I say we close even today!

1 · Reply

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Apr 1, 2026, 4:05 PM EDT - 19 days ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Feb 24, 2026, 4:05 PM EST - 7 weeks ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 2 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 3 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 12, 2026, 9:00 AM EST - 3 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Dec 18, 2025, 9:00 AM EST - 4 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 4 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Nov 10, 2025, 9:00 AM EST - 5 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 6, 2025, 4:05 PM EST - 5 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 6 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 7 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Aug 27, 2025, 9:00 AM EDT - 8 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 4:05 PM EDT - 9 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

May 30, 2025, 1:00 PM EDT - 11 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

May 28, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results

May 1, 2024, 9:00 AM EDT - 2 years ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Apr 8, 2024, 12:05 PM EDT - 2 years ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 3, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Mar 19, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 11, 2024, 9:00 AM EDT - 2 years ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

Mar 5, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

Feb 23, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Resignation of Board Member

AngelosProject Apr. 20 at 11:51 PM

$VITL $MRAM $CROX $ABCL lbcd

0 · Reply

SpaceRunners Apr. 20 at 10:49 PM

$CLOV $RVSN $PFE $ABCL XO

1 · Reply

AngelosProject Apr. 20 at 10:21 PM

$ABCL $GNS $GEVO $MRAM canc

0 · Reply

8008track Apr. 20 at 9:30 PM

$ABCL AbCellerites growing https://x.com/tyler_bosserman/status/2046306534477500711?s=46&t=19IS2lnKv9JueG0DGj5x7Q

0 · Reply

tradersunion353 Apr. 20 at 8:42 PM

$ABCL POS performance as usual. Lets see with that data on earnings day. Too much overhyped and very disaapointing performance stock,.

0 · Reply

AngelosProject Apr. 20 at 8:28 PM

$ABCL $ROG $MDCX $CUE ank

1 · Reply

AcceleratorModel Apr. 20 at 8:00 PM

$ABCL got sum at the bell , 3.91

0 · Reply

UncleTomFlorida Apr. 20 at 7:48 PM

$ABCL https://x.com/JackPrescottX/status/2046310840140534077?s=20

0 · Reply

DragonAlgo Apr. 20 at 7:15 PM

0 · Reply

Rastafari Apr. 20 at 7:12 PM

$ABCL quick poll: do we close up, down or even today. It seems the big boys are trying to keep it down. I say we close even today!

1 · Reply

Plan2TradeTrade2Plan Apr. 20 at 7:08 PM

$ABCL why wait? No material information?

0 · Reply

Nardwuar_ Apr. 20 at 6:38 PM

$ABCL I’m not in this but I just keep thinking back to the idea that Thiel still holds all his shares. He’s down like 80-90% too lol! Thiel probably realizes that this company just needed time to get everything right and organize before they have the chance of chucking patented treatments left and right worth billions. Only make sense long term. It was over a billion he invested, now worth 50 mil….

0 · Reply